MannKind to Discuss U.S. Commercialization Update for Afrezza®
– Analyst Call Scheduled for April 19, 2016 at 5:00 PM EDT –
VALENCIA, Calif., April 11, 2016 -- MannKind Corporation (MNKD) (MNKD) will host an analyst call for the investment community to learn about the company’s general commercialization strategy in the US for Afrezza® (insulin human) Inhalation Powder. MannKind has recently assumed responsibility for the worldwide development and commercialization of Afrezza from Sanofi and will begin to distribute Afrezza in the third quarter. Until that time, Sanofi will continue to distribute Afrezza from its existing inventory of product.
To participate in the live call by telephone, please dial (888) 224-7957 or (303) 223-4394 and use the participant passcode: 21809665. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.
- Published: 11 April 2016
- Written by Editor